# Vigil Neuroscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vigil-neuroscience

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.vigilneuro.com
- Total disclosed funding: $120M
- Latest round: Series B (Aug 13, 2021)
- Investors on record: 14

## About

Founded in 2020 and based in Massachusetts, US, Vigil Neuroscience, Inc., a.k.a. Vigil Neuro develops microglia-based therapies for the treatment of neurodegenerative diseases. In August 2021, Vigil Neuroscience, Inc. raised USD 90 million in a Series B funding led by Vida Ventures, with participation from Cormorant Asset Management, LLC, Deep Track Capital, Invus, Lightstone Ventures, Logos Capital Partners, OrbiMed Advisors, Pivotal bioVenture Partners, Rock Springs Capital, Surveyor Capital, Atlas Venture, Hatteras Venture Partners, and Northpond Ventures. As of November 2021, Vigil Neuroscience, Inc. has raised a total of USD 120 million in funding and Dr. Ivana Magovcevic-Liebisch is President and CEO of the company.

Vigil Neuroscience, Inc. develops VGL101, a fully human monoclonal antibody, and small molecule agonists of triggering receptor on myeloid cells 2 (TREM2), which is a microglia sensor that mediates responses to environmental signals to maintain brain homeostasis.

Vigil Neuroscience, Inc. plans to use its proceeds from a Series B funding to progress a monoclonal antibody TREM2 agonist, through phase 1 studies, advance its small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.

## Funding rounds

- Series B, Aug 13, 2021, $90M — Atlas Venture, OrbiMed Advisors, Hatteras Venture Partners, Invus [DUP], Lightstone Ventures, Rock Springs Capital, Cormorant Asset Management, Pivotal Life Sciences, Vida Ventures, Surveyor Capital, Northpond Ventures, Logos Capital, Deep Track Capital
- Series A, Sep 18, 2020, $30M — Atlas Venture, Alexandria Venture Investments, Hatteras Venture Partners, Northpond Ventures

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series A, Series B
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Invus [DUP] — Series B
- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Series B
- Rock Springs Capital — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series B
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series B
- Surveyor Capital — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B